References
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90. https://doi.org/10.3322/caac.20107
- Jung KW, Won YJ, Kong HJ, Lee ES. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015. Cancer Res Treat 2018;50:303-16. https://doi.org/10.4143/crt.2018.143
- Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51. https://doi.org/10.1056/NEJMoa032709
- Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 2011;29:1465-71. https://doi.org/10.1200/JCO.2010.33.6297
- Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27:3109-16. https://doi.org/10.1200/JCO.2008.20.6771
- Andre T, Quinaux E, Louvet C, Colin P, Gamelin E, Bouche O, et al. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. J Clin Oncol 2007;25:3732-8. https://doi.org/10.1200/JCO.2007.12.2234
- O'Connell MJ, Laurie JA, Kahn M, Fitzgibbons RJ, Jr., Erlichman C, Shepherd L, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998;16:295-300. https://doi.org/10.1200/JCO.1998.16.1.295
- Cersosimo RJ. Oxaliplatin-associated neuropathy: a review. Ann Pharmacother 2005;39:128-35. https://doi.org/10.1345/aph.1E319
- Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, et al. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. N Engl J Med 2018;378:1177-88. https://doi.org/10.1056/NEJMoa1713709
- Andre T, Vernerey D, Mineur L, Bennouna J, Desrame J, Faroux R, et al. Three versus 6 months of oxaliplatin-based adjuvant chemotherapy for patients with stage III colon cancer: disease-free survival results from a randomized, open-label, international duration evaluation of adjuvant (IDEA) France, Phase III Trial. J Clin Oncol 2018;36:1469-77. https://doi.org/10.1200/JCO.2017.76.0355
- Kim SH, Kim W, Kim JH, Woo MK, Baek JY, Kim SY, et al. A Prospective study of chronic oxaliplatin-induced neuropathy in patients with colon cancer: long-term outcomes and predictors of severe oxaliplatin-induced neuropathy. J Clin Neurol 2018;14:81-9. https://doi.org/10.3988/jcn.2018.14.1.81
- Baek KK, Lee J, Park SH, Park JO, Park YS, Lim HY, et al. Oxaliplatin-induced chronic peripheral neurotoxicity: a prospective analysis in patients with colorectal cancer. Cancer Res Treat 2010;42:185-90. https://doi.org/10.4143/crt.2010.42.4.185
- Lonardi S, Sobrero A, Rosati G, Di Bartolomeo M, Ronzoni M, Aprile G, et al. Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial. Ann Oncol 2016;27:2074-81. https://doi.org/10.1093/annonc/mdw404